Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, November 22, 2016 ) Publisher Drug Report, "Alimta- Drug Insights, 2016" highlights the Alimta marketed details, pipeline status and the Global API Manufacturers along with the location. The Publisher's report covers the Global Market Assessment of the Alimta covering the total sales estimation and also provides the Alimta sales performance during the historical period and forecast period to 2018. Publisher's Report also covers the detailed clinical assessment of Alimta, patents information and exclusivity data, route of synthesis, competitive landscape, and generic players. In addition to this, Publisher's Report provides the SWOT analysis for the Alimta. Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated drug. For more information about this report: http://www.reportsweb.com/Alimta-drug-insights-2016
Report Scope
-A review of the Alimta based on information derived from company and industry-specific sources -Coverage of the Marketed data of the Alimta on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification -Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and API Manufactures in China & India for Alimta with location details -Patent Expiry Timeline and Exclusivity Details -Route of Synthesis of the API -Global Forecasted Sales Figure to 2018 -Qualitative and quantitative assessment of market space -SWOT Analysis
Reasons to buy
-Evaluate the marketing status and exclusivity details of Alimta to exploit opportunities for generic drug development opportunities. -Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Alimta. -API intelligence over Alimta and gaining primary intelligence over Active Ingredients manufacturers across the globe. -Understanding the chemical route of synthesis of Alimta. -Uncovering opportunities in the rapidly growing the US market -Stay ahead of competition by understanding the changing competitive landscape -Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential -Make more informed business decisions from insightful and in-depth analysis of the drug's performance -Obtain sales forecast for currently marketed drug for to 2018
Request Sample Copy at http://www.reportsweb.com/inquiry&RW000182620/sample
Table of Contents
1. DelveInsight Report Introduction 2. Alimta Overview 2.1 Market Competition 2.3 Competitors in Development 3 Global Sales Assessment 3.1 Historical Sales of Alimta 3.2 Forecasted Sales of Alimta 4 Product Description 4.1 Mechanism of Action 4.2 Pharmacodynamic Properties 4.3 Pharmacokinetic Properties 5 Marketed Details 5.1 United States 5.2 Europe 6 Patent Information 6.1 Patent Numbers and Expiry Details 6.2 Patent and Exclusivity Expiry Assessment United States (US) 6.3 Patent Details 7 Route of Synthesis 8 Global API Manufacturers Assessment 8.1 The United States Drug Master File (US DMF) 8.2 The Europe Drug Master File (EUDMF)/Active Substance Master File (ASMF) 8.3 The Active Pharmaceutical Ingredient (API) Manufacturers in China 8.4 The Active Pharmaceutical Ingredient (API) Manufacturers in India 9 Generic Players 10 The Pipeline Coverage 11 Clinical Trials Information 11.1 Clinical Trials by Zone 12 Company Profile 12.1 Company Summary 12.2 Company Financials 13 SWOT Analysis
Inquire before Buying at http://www.reportsweb.com/inquiry&RW000182620/buying
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
Source: EmailWire.com
|
|
|
|